Regulating effects of GSK650394 on behavior and hippocampal neurotrophy in chronic stress model of depression in rats

doi:10.16352/j.issn.1001-6325.2022.01.013

Abstract

Abstract: Objective To investigate the protective effect of serum and glucocorticoid-regulated kinase 1(SGK1) inhibitor GSK650394 on depression-like behaviors and hippocampus neurotrophy in depressive model rats. Methods SD rats were randomly divided into control group, depression model group and GSK650394 group. Depression model was established by chronic mild unpredictable stress. The behavioral changes of the SD rats were observed by forced swimming, 1% sugar consumption test and Morris water maze. The changes of corticosterone(CORT) and monoamine neurotransmitters in plasma and serum were observed by ELISA. The changes of BDNF, NT-3 and NGF in hippocampus were detected by Western blot. Results Compared with the control group, the model group showed that sucrose preference decreased and swimming immobility time increased significantly(P＜0.01). Escape latency(EL) and latency time(Lat.T) prolonged significantly (P＜0.05 or P＜0.01) and the content of CORT in plasma increased significantly (P＜0.01). The content of 5-HT, NE in serum and the expression of BDNF, NT-3, NGF in hippocampus significant increased in the model group. Compared with model group, GSK650394 significantly increased sucrose preference, decreased immobility time(P＜0.05 or P＜0.01), shortened EL and Lat.T(P＜0.05), decreased the content of CORT in plasma (P＜0.01) and enhanced the level of 5-HT and NE in serum (P＜0.01) and also promoted the expression of NT-3, BDNF and NGF in hippocampus. Conclusions SGK1 inhibitor GSK650394 can significantly relieve depression like behavior potentially through improving the nutrition profile of neurotrophin in hippocampus.

Key words: depression, glucocorticoid-regulated kinase 1(SGK1), GSK650394, hippocampus, neurotrophin

CLC Number:

R749.4

LIU Dan, LIN Xiao-yuan, YANG Hui, LIU Tong-tong, LIU Ping-an, MENG Pan. Regulating effects of GSK650394 on behavior and hippocampal neurotrophy in chronic stress model of depression in rats[J]. Basic & Clinical Medicine, 2022, 42(1): 89-93.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.01.013

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I1/89

References

[1]GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018,392:1789-1858.
[2]Shadrina M, Bondarenko EA, Slominsky PA. Genetics factors in major depression disease[J]. Front Psychiatry, 2018,9:334.doi: 10.3389/fpsyt.2018.00334.
[3]Cattaneo A, Riva MA. Stress-induced mechanisms in mental illness: a role for glucocorticoid signalling[J]. J Steroid Biochem Mol Biol, 2016,160:169-174.
[4]Dattilo V, Amato R, Perrotti N, et al. The emerging role of SGK1 (serum- and glucocorticoid-regulated kinase 1) in major depressive disorder: hypothesis and mechanisms[J]. Front Genet, 2020,11:826. doi: 10.3389/fgene.2020.00826.
[5]Anacker C, Cattaneo A, Musaelyan K, et al. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis[J]. Proc Natl Acad Sci U S A, 2013,110:8708-8713.
[6]韩远山, 王宇红, 孟盼, 等. 百事乐胶囊对抑郁模型大鼠海马神经元显微结构及凋亡的影响[J]. 时珍国医国药, 2015,26:44-47.
[7]Sowa-Kuc＇ma M, Pańczyszyn-Trzewik P, Misztak P, et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant[J]. Pharmacol Rep, 2017,69:595-601.
[8]Luscher B, Fuchs T. GABAergic control of depression-related brain states[J]. Adv Pharmacol, 2015,73:97-144.
[9]Meng P, Zhu Q, Yang H, et al. Leonurine promotes neurite outgrowth and neurotrophic activity by modulating the GR/SGK1 signaling pathway in cultured PC12 cells[J]. Neuroreport, 2019,30:247-254.
[10]Anacker C, Cattaneo A, Luoni A, et al. Glucocorticoid-related molecular signaling pathways regulating hippocam-pal neurogenesis[J]. Neuropsychopharmacology, 2013,38:872-883.
[11]于莹, 张功, 韩涛, 等. 中成药辅助治疗肝郁脾虚型抑郁症的网状Meta分析[J]. 中国中药杂志, 2019,44:5217-5224.
[12]刘效巍,许晶,李晓秋,等.慢性应激抑郁模型大鼠脑内5HT_(1A)和5-HT_(2A)受体的变化[J].基础医学与临床,2004:174-178.
[13]Wang X, Xie Y, Zhang T, et al. Resveratrol reverses chronic restraint stress-induced depression-like behaviour: Involvement of BDNF level, ERK phosphorylation and expression of Bcl-2 and Bax in rats[J]. Brain Res Bull, 2016,125:134-143.
[14]王涵,李娜,文威,等.慢性应激致大鼠抑郁行为涉及海马形态变化和BDNF表达降低[J].基础医学与临床,2011,31:565-569.
[15]Aloe L, Rocco ML, Balzamino BO, et al. Nerve growth factor: a focus on neuroscience and therapy[J]. Curr Neuropharmacol, 2015,13:294-303.
[16]Yang Z, Zhang A, Duan H, et al. NT3-chitosan elicits robust endogenous neurogenesis to enable functional recovery after spinal cord injury[J]. Proc Natl Acad Sci U S A, 2015,112:13354-13359.
[17]Schniepp R, Kohler K, Ladewig T, et al. Retinal colocalization and in vitro interaction of the glutamate transporter EAAT3 and the serum- and glucocorticoid-inducible kinase SGK1 [correction][J]. Invest Ophthalmol Vis Sci, 2004,45:1442-1449.